StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 29 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Next report date, year-over-year trend, and recent quarter history.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $13.15 | $13.53 | +2.89% | 4.7M |
| 05-19 | $13.53 | $13.86 | +2.44% | 2.0M |
| 05-20 | $13.89 | $15.04 | +8.28% | 1.7M |
| 05-21 | $14.94 | $15.76 | +5.49% | 2.8M |
| 05-22 | $15.74 | $14.96 | -4.92% | 2.0M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows TNDM's percentile within the scored universe — observational ranking, not a recommendation.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-04 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $259.59M | $247.22M | $1.01B | $724.35M | $475.10M |
Operating Income | Not available | $-17.43M | $-187.26M | $-195.55M | $-172.69M |
Net Income | Not available | $-20.39M | $-204.71M | $-204.12M | $-182.96M |
EPS (Diluted) | $-0.33 | $-0.30 | $-3.04 | $-3.04 | $-2.74 |
Total Assets | Not available | $1.15B | $881.11M | $874.65M | $875.74M |
Total Liabilities | Not available | $1.02B | $725.94M | $741.69M | $742.45M |
Cash & Equivalents | Not available | $179.32M | $90.63M | $91.95M | $64.11M |
Free Cash Flow OCF − CapEx | Not available | $4.79M | $-29.67M | $-32.77M | $-36.95M |
Shares Outstanding | Not available | 68.50M | 68.29M | 67.77M | 67.53M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.